thereby paving the path for dedicated phase 2b trials in these cancer types, with more indications being tested. Given zero CRS toxicity treating patients in an outpatient setting, and substantial ...

Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses ...

At Fred Hutch Cancer Center and University of Washington Medical Center, we have an experienced team that provides CRS-HIPEC. Many of our patients receive all their cancer care through Fred Hutch and ...

The study showed that all doses of POLB 001 significantly reduced clinically observed Cytokine Release Syndrome (CRS) scores, reinforcing its potential in preventing and treating cancer ...

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple ...

Standard premedications included acetaminophen, diphenhydramine, and dexamethasone. No patients received prophylactic tocilizumab, and CRS (if present) was managed in the inpatient setting. There was ...

“So God forbid the cancer comes back, you have a defense system ... including significantly reduced risks of CRS and immune effector cell-associated neurotoxicity syndrome (ICANS), as well ...